Important Information for Patients Receiving



Please read all of the following information carefully before your treatment with EYLEA begins.

EYLEA is a prescription medicine that is injected into the eye to treat neovascular (wet) Age-related Macular Degeneration (AMD). EYLEA has been approved by the US Food and Drug Administration for the treatment of wet AMD.

BEFORE YOU ARE GIVEN EYLEA

- Tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
- Tell your doctor if you have glaucoma.
- EYLEA should not be used (contraindicated) in patients who have an infection in or around the eye (ocular or periocular infections), eye pain or redness (active intraocular inflammation) or known allergies (hypersensitivity) to any of the ingredients of EYLEA, including aflibercept.
- EYLEA is not recommended for patients who are pregnant, breast feeding, or under 18 years of age. Please tell your doctor if any of these apply to you.

AFTER YOU HAVE BEEN GIVEN EYLEA

- You may experience some temporary visual disturbances after injection and associated eye exams.
 Do not drive or use machinery for as long as these last.
- Injection with EYLEA may trigger an acute increase in eye pressure (intraocular pressure), in some patients, within 60 minutes of the injection. Sustained increases in intraocular pressure can occur with repeated dosing. Your doctor may monitor this after each injection.
- Injections into the eye, including those with EYLEA, have been associated with an infection of the eye (endophthalmitis) and a separation of the light-sensitive membrane in the back of the eye (retina) from its supporting layers (retinal detachment). These conditions may be associated with eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, and increased sensitivity to light. Please contact your doctor immediately if you develop any such signs or symptoms because it is important to have any symptoms diagnosed and treated as soon as possible.

PLEASE SEE REVERSE SIDE FOR POSSIBLE SIDE EFFECTS.

Please see the accompanying full Prescribing Information for EYLEA in pocket

Additional Important Information for Patients Receiving



POSSIBLE SIDE EFFECTS

As with all medicines, EYLEA can cause side effects.

Serious side effects related to the injection procedure are rare but can occur and include infection inside the eye (endophthalmitis) and a separation of the light-sensitive membrane in the back of the eye (retina) from its supporting layers (retinal detachment), an increase of pressure inside the eye, and clouding of the lens (traumatic cataract).

There is a potential risk of blood clots leading to heart attack or stroke (arterial thromboembolic events) following injections into the eye with EYLEA and other drugs similar to it. The incidence of arterial thromboembolic events in EYLEA clinical trials was low.

Other more common but less serious side effects have been reported in clinical trials and may be related to the injection procedure or the medicine. Always discuss any suspected side effects with your doctor. These include bloodshot eye (conjunctival hemorrhage), eye pain, moving spots in vision (vitreous floaters) or flashes of light which may or may not be related to detachment of the vitreous (the gel-like substance inside the eye) from the retina (vitreous detachment).

- If any of the side effects gets serious, or if you notice any side effects not listed, please tell your doctor.
- For additional safety information, talk to your doctor.
- PLEASE SEE REVERSE SIDE FOR IMPORTANT INFORMATION FOR BEFORE AND AFTER TREATMENT WITH EYLEA.

Please see the accompanying full Prescribing Information for EYLEA in pocket

EYLEA is a trademark of Regeneron Pharmaceuticals, Inc.